IDEAYA Biosciences Strategy and Business Model

Executive Overview

IDEAYA Biosciences is a South San Francisco-based precision oncology company founded in 2015 that focuses on discovering and developing targeted cancer medicines for biomarker-defined patient populations. Its strategic identity is unusually clear for a clinical-stage biotech: IDEAYA is built around synthetic lethality, precision medicine, and translational science designed to match a drug candidate to a specific molecular vulnerability such as GNAQ/GNA11 mutations, MTAP deletion, or homologous recombination deficiency. As of 2024, IDEAYA had no approved commercial products, so its most recently reported annual revenue of #N/A was collaboration-based rather than product-based. The lead program, darovasertib, is the company’s most important near-term asset, especially in metastatic uveal melanoma, while IDE397 and IDE161 extend the platform into broader genetically defined solid tumors. IDEAYA operates in the biotechnology industry rather than diversified pharmaceuticals: it is asset-light in manufacturing, partnership-oriented where useful, and heavily dependent on R&D execution. For readers assessing the strategy of IDEAYA Biosciences, the central question is whether it can convert differentiated biology and biomarker selection into clinically meaningful data, regulatory progress, and eventually a focused oncology commercialization model.

IDEAYA Biosciences at a Glance

Logo
Common name	IDEAYA Biosciences
Full legal name	IDEAYA Biosciences, Inc.
Headquarters	South San Francisco, California, United States
Ownership	Public company
Ticker	IDYA
Exchange	NASDAQ
Market Cap	$3.32B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2015; initial public offering in 2019; expanded through major synthetic-lethality collaborations and the advancement of darovasertib, IDE397, and IDE161 into the clinic by 2024
Industry or industries	Biotechnology; precision oncology; oncology drug discovery and development
Key products or services	Investigational precision oncology therapies; synthetic-lethality drug discovery; research and licensing collaborations
Geographic footprint	U.S.-centered operations with international clinical development and collaboration reach
Business segments as officially reported	One operating and reportable segment focused on the discovery and development of precision medicine oncology therapies
Company website	https://www.ideayabio.com/

1. What Is the Strategy of IDEAYA Biosciences?

IDEAYA’s public strategy is best understood through the Playing to Win framework. The company is not trying to be a broad oncology company across dozens of modalities. It is trying to build a focused precision-oncology business around genetically defined targets where biomarker selection can improve the odds of clinical success.

1. 1a. What is the winning aspiration of IDEAYA Biosciences?

   IDEAYA’s winning aspiration is to become a leading precision-medicine oncology company by developing targeted therapies for patients whose tumors carry actionable molecular vulnerabilities. In practical terms, winning means generating compelling clinical data, advancing at least one lead asset into a potential registration path, and creating a repeatable engine for discovering synthetic-lethality medicines beyond a single program. Because IDEAYA remained pre-commercial as of 2024, the near-term scorecard is clinical proof of concept, regulatory progress, and portfolio value creation rather than established product sales.

2. 1b. Where does IDEAYA Biosciences play?

   IDEAYA plays in biomarker-defined oncology, especially solid tumors where a clear genetic or pathway-based hypothesis can guide both drug design and patient selection. Its current focus includes metastatic uveal melanoma driven by GNAQ or GNA11 pathway biology, MTAP-deleted solid tumors, and homologous recombination-deficient cancers. The company is also concentrated by modality: it has emphasized targeted small molecules and translationally informed clinical development rather than broad immuno-oncology, large-scale biologics, or primary-care medicines.

3. 1c. How does IDEAYA Biosciences plan to win?

   IDEAYA’s plan to win is based on being more selective than a traditional oncology developer. It aims to identify high-value cancer subsets, design drugs against the relevant biology, and use biomarkers to enroll the patients most likely to respond. That creates a differentiated value proposition: better signal detection in trials, potentially faster development in rare or molecularly defined populations, and the possibility of premium rare-oncology economics if efficacy is strong. The darovasertib strategy in uveal melanoma and the IDE397 strategy in MTAP-deleted tumors both fit this pattern.

4. 1d. What capabilities must IDEAYA Biosciences have in place?

   To execute this strategy, IDEAYA needs strong translational biology, medicinal chemistry, biomarker development, and clinical trial design capabilities. It also needs the ability to identify rare patients efficiently, manage regulatory interactions in oncology, coordinate contract research and manufacturing partners, and run a portfolio where some assets are wholly owned while others are partnered. In a company like IDEAYA, the quality of science alone is not enough; the operational ability to convert biology into clean clinical data is critical.

5. 1e. What management systems does IDEAYA Biosciences require?

   IDEAYA needs stage-gated portfolio governance, disciplined capital allocation, and strong cross-functional program management. Management systems must connect discovery, translational medicine, clinical operations, chemistry, manufacturing, and controls, regulatory affairs, and business development. The company also needs robust alliance-management processes for large-pharma partnerships and a financing discipline centered on cash runway to major data catalysts. For a clinical-stage biotech, these systems are strategically important because a delay in enrollment, assay readiness, or manufacturing can materially shift value creation.

2. What Are the Current Strategic Initiatives of IDEAYA Biosciences?

Advance darovasertib toward a potential first commercial product

IDEAYA’s most important near-term initiative is the continued development of darovasertib, especially in metastatic uveal melanoma. Public company materials through 2024 consistently positioned darovasertib as the lead value driver. The strategic emphasis has been on showing that PKC inhibition, particularly in combination with crizotinib, can deliver clinically meaningful activity in a disease with few effective systemic options. This matters especially in patients who are not eligible for tebentafusp because they are not HLA-A*02:01 positive, although darovasertib’s commercial relevance is not limited to that subgroup.

Broaden the darovasertib opportunity beyond the initial metastatic setting

IDEAYA has also discussed expansion opportunities for darovasertib beyond a single metastatic use case. The logic is straightforward: if the drug shows differentiated activity and tolerability, the same asset may have value in additional settings or adjacent PKC-driven tumors. Publicly discussed opportunities have included broader uveal melanoma use cases and PRKC-related tumor biology. The first job, however, is to secure strong evidence in the lead indication.

Push IDE397 toward clinical proof of concept in MTAP-deleted tumors

IDE397 is IDEAYA’s key pan-tumor synthetic-lethality program. The strategic initiative here is to establish a meaningful clinical signal in MTAP-deleted solid tumors, a biomarker-defined population that spans multiple cancer types. This program is important because it could expand IDEAYA beyond rare disease into a larger precision-oncology opportunity while remaining anchored in a genetically selected patient population. The company’s public messaging has emphasized both the importance of monotherapy data and the possibility that combinations may ultimately be needed to maximize efficacy.

Advance IDE161 and build a multi-asset synthetic-lethality pipeline

IDE161, a PARG inhibitor, represents another important strategic initiative: reducing dependence on a single lead program by building multiple shots on goal in DNA-damage-repair and synthetic-lethality biology. For IDEAYA, this is not just diversification. It is a way to demonstrate that the company’s discovery approach can repeatedly produce clinically relevant assets.

Use partnerships selectively rather than outsource the whole business model

IDEAYA has historically used large-pharma collaborations to add capital, external validation, and scientific reach. The strategic pattern is selective partnering rather than full dependence on partners. That balance matters: wholly owned assets can create more upside if successful, while partnerships can help fund discovery and reduce risk.

Maintain capital flexibility to fund parallel development programs

As a pre-commercial biotech, IDEAYA’s ability to execute its strategy depends on financing. A recurring strategic initiative has therefore been to keep a balance sheet strong enough to advance multiple clinical programs at once rather than serializing development around only one asset. For IDEAYA, capital strategy is inseparable from corporate strategy.

3. What Is the Business Model of IDEAYA Biosciences?

IDEAYA’s business model is that of a clinical-stage precision-oncology biotech, not a mature pharmaceutical company. As of 2024, it had no approved product sales. That means the current economic model is built on a mix of collaboration revenue, milestone potential, and equity financing while the company funds research and clinical development.

What customers actually buy

Today, the main counterparties that pay IDEAYA are not hospitals or retail pharmacies. They are collaboration partners that buy access to program rights, research collaboration, or future option value. If IDEAYA succeeds commercially, future customers would be oncologists, cancer centers, and health systems prescribing targeted therapies for biomarker-selected patients, with payers and diagnostic-testing ecosystems acting as important economic gatekeepers.

Recurring versus one-time economics

Current revenue is mostly non-recurring or lumpy. Upfront payments, milestones, and collaboration accounting do not behave like a recurring subscription business. If IDEAYA reaches commercialization, revenue would likely become repeat-driven through ongoing treatment demand, refills, and additional prescribing in eligible patient populations. Until then, the business remains development-stage and milestone-driven.

How pricing power works

IDEAYA has no commercial pricing yet, but the likely future pricing framework is specialty oncology. In rare or biomarker-defined cancers, pricing power can be meaningful if a drug demonstrates strong efficacy, durability, and acceptable safety, especially where treatment alternatives are limited. That said, pricing power in oncology is never absolute; payers, health technology assessment bodies outside the United States, and guideline bodies all matter.

Why the business mix matters

The mix between wholly owned assets and partnered assets is strategically important. A wholly owned program such as a successful lead oncology drug can create much larger long-term economics. A partnered program generates lower eventual economics per asset but can reduce financing pressure and broaden the portfolio.

What drives margins and cash generation

Today, IDEAYA’s operating profile is dominated by research and development expense, clinical trial spend, and the infrastructure needed to support a public biotech. Product gross margin is not yet meaningful because there are no marketed products. If the company launches an oral small-molecule oncology product, gross margins could eventually be attractive because manufacturing costs are usually low relative to specialty oncology pricing. For now, the critical financial output is not operating margin but cash runway to key clinical inflection points.

4. What Products and/or Services Does IDEAYA Biosciences Sell?

As of 2024, IDEAYA did not sell an approved commercial medicine. Its most important “products” were investigational drug candidates and the licensing or collaboration rights associated with its precision-oncology pipeline.

The economically most important offering today is still pipeline value, not product sales. Darovasertib appears to be the most strategically important asset because it is closest to potential commercialization. IDE397 is important because it offers a larger biomarker-defined market opportunity if the biology translates clinically. IDE161 and earlier-stage programs matter as follow-on growth drivers and as evidence that IDEAYA’s discovery engine is repeatable.

5. What Are the Key Competitors or Peers of IDEAYA Biosciences?

IDEAYA competes program by program rather than through one broad company-level market. Some competitors are direct disease competitors in uveal melanoma; others compete for the same biomarker-defined patient populations or for investor attention in synthetic-lethality oncology.

IDEAYA also competes for clinical trial patients, key opinion leaders, biomarker-tested patients, licensing opportunities, and investor capital. In biotech, those forms of competition can matter almost as much as product competition.

6. What Is the Marketing Strategy of IDEAYA Biosciences?

IDEAYA is still pre-commercial, so its marketing strategy is not consumer advertising or broad pharmaceutical promotion. At this stage, marketing is mostly scientific positioning.

• Data-driven scientific communication: IDEAYA’s main marketing assets are clinical data releases, conference presentations, publications, and interactions with key opinion leaders in oncology and ocular oncology.
• Biomarker education: Because IDEAYA’s programs depend on genomic selection, part of the “marketing” task is helping the market understand why a biomarker such as MTAP deletion or GNAQ/GNA11 mutation matters clinically.
• Targeted specialist focus: If darovasertib reaches market, the likely launch model would center on a small number of specialist accounts and oncology centers rather than broad mass-market promotion.

That means marketing is a supporting capability today, not the primary differentiator. The differentiator is the data. Over time, however, marketing and medical affairs could become more important if IDEAYA needs to drive testing, guideline inclusion, referral patterns, and payer acceptance in a rare-oncology setting.

7. What Are the Key Customer Segments of IDEAYA Biosciences?

IDEAYA’s customer picture is unusual because it is a clinical-stage biotech. The relevant customer groups differ between the current period and a future commercial period.

• Current economic customers: Large-pharma collaboration partners that pay for access to pipeline assets, discovery capabilities, or future options.
• Current clinical stakeholders: Investigators, academic cancer centers, trial sites, and patients enrolled in biomarker-driven studies.
• Future prescribing customers: Medical oncologists, ocular-oncology specialists, and cancer centers that would prescribe a commercialized IDEAYA therapy.
• Future economic gatekeepers: Commercial payers, government payers, and health technology assessment bodies outside the United States.
• Testing ecosystem participants: Genomic testing labs and diagnostic networks that identify eligible patients.

IDEAYA is not diversified across many end markets. It is concentrated in oncology, and within oncology it is concentrated in molecularly defined subpopulations. That creates both advantage and risk: the commercial model can be highly focused, but each program depends heavily on accurate patient identification and strong clinical differentiation.

8. What Is the Sales Model of IDEAYA Biosciences?

IDEAYA does not yet have a traditional commercial sales model because it has no approved products. Its current “sales” activity is primarily business development and partner management.

Current model

Today, IDEAYA reaches the market through collaboration agreements, licensing discussions, and clinical-trial execution rather than through distributors, wholesalers, or a field sales force. Patients access its therapies only through clinical studies.

Likely future model if a product is approved

Based on the company’s disease focus, the most plausible commercial model would be a targeted specialty-oncology field force in the United States, supported by medical science liaisons, market-access capabilities, and diagnostic-testing support. Outside the United States, IDEAYA could choose between building selectively or partnering, depending on the size of the opportunity and capital priorities. That is an inference from the economics of rare oncology, but it fits the company’s portfolio.

Why the channel structure matters

A concentrated specialty channel would give IDEAYA strong customer intimacy at a limited number of key accounts, which can be an advantage in rare cancers. It also means growth depends less on broad advertising and more on account segmentation, physician education, patient-finding, and reimbursement execution. Those are discrete workstreams where outside experts can add value.

9. In What Geographies Does IDEAYA Biosciences Operate?

IDEAYA’s operating footprint is centered in the United States, with headquarters in South San Francisco. That is the core location for corporate leadership, discovery activity, and development oversight.

Its clinical footprint is broader than its physical office footprint. Because IDEAYA works in rare and biomarker-selected cancers, patient recruitment often requires multi-center and international clinical studies. Public materials indicate a development model that reaches beyond the United States through trial sites, collaborators, and outsourced manufacturing and research partners.

IDEAYA does not have the kind of global commercial infrastructure associated with large pharmaceutical companies. It is better described as a U.S.-based biotech with global clinical and partnership reach. If it commercializes successfully, geography will become a more explicit strategic choice: build selected markets directly, or license ex-U.S. rights to partners.

10. Who Are the Owners of IDEAYA Biosciences?

IDEAYA is a publicly traded company listed on Nasdaq. As of the company’s 2024 public disclosures, it did not appear to have a controlling shareholder. Ownership was primarily institutional, which is typical for a development-stage biotech.

Public filings over time have shown a shareholder base that includes biotechnology-focused investors, legacy venture backers, and broad index managers. Entities affiliated with The Column Group have historically been important shareholders, and firms such as Vanguard and BlackRock can also appear in the register through public-market holdings. Exact ownership percentages are time-sensitive and should be checked against the latest proxy, 13D, 13G, and 13F filings.

11. How Is IDEAYA Biosciences Organized?

IDEAYA is organized as a single operating and reportable segment, which is common for a clinical-stage biotech focused on one core mission. It is not a multi-division pharmaceutical conglomerate.

At a practical level, the company appears to be organized around:

• Discovery and translational science for target identification, biomarker work, and preclinical validation
• Clinical development for darovasertib, IDE397, IDE161, and other advancing assets
• Chemistry, manufacturing, and controls plus technical operations, largely coordinated with outside vendors
• Regulatory, medical, and safety functions to support oncology development
• Business development and alliance management for large-pharma collaborations
• Corporate functions including finance, legal, and investor relations

The economically meaningful structure is therefore program-centric rather than brand-centric or geography-centric.

12. How Does IDEAYA Biosciences Operate?

IDEAYA operates by moving from molecular hypothesis to biomarker-selected clinical trial. The day-to-day value creation process is different from that of a commercial pharma company:

1. Identify a target or synthetic-lethal relationship with enough biological rationale and patient-selection potential.
2. Design and optimize a small-molecule candidate with drug-like properties and a defendable intellectual-property position.
3. Build a biomarker strategy so the right patients can be identified in trials.
4. Run preclinical validation and manufacturing preparation, usually with heavy use of specialized external partners.
5. Conduct early clinical studies to find the dose, characterize safety, and test whether the biology translates into patient benefit.
6. Refine development strategy around monotherapy, combination therapy, and the most attractive registrational pathway.

The main operational bottlenecks are highly specific to precision oncology: finding enough biomarker-positive patients, synchronizing drug supply with clinical enrollment, obtaining reliable assay results, and deciding quickly whether a given asset merits accelerated investment. In IDEAYA’s case, good operations mean reducing the time between a biological insight and a decision-quality clinical readout.

13. What Are the Growth Opportunities for IDEAYA Biosciences?

The biggest growth constraint is simple: IDEAYA must first convert its science into durable clinical evidence. For a company at this stage, growth opportunities are real, but they are contingent rather than assured.

14. What Is the History of IDEAYA Biosciences?

IDEAYA was founded in 2015. Public company materials identify Yujiro Hata, M.D. as founder and chief executive officer. From the beginning, the company was built around precision oncology and synthetic lethality rather than broad therapeutic diversification.

• 2015: IDEAYA is established in the Bay Area biotech ecosystem with a focus on targeted oncology and biomarker-led development.
• 2019: IDEAYA completes its initial public offering, giving it access to the public capital markets needed to fund multi-year oncology development.
• 2020: The company deepens its external ecosystem through major collaborations, including alliances with GSK and Gilead, reinforcing its synthetic-lethality strategy.
• 2020 onward: Darovasertib becomes a central strategic asset, moving IDEAYA closer to a potential commercial rare-oncology opportunity.
• 2022-2024: IDEAYA advances a broader clinical pipeline, including IDE397 and IDE161, while strengthening its balance sheet to support multiple development programs.

The history of IDEAYA is less about corporate reinvention and more about focused evolution from platform concept to multi-asset clinical-stage biotech.

15. What Are the Key Suppliers to IDEAYA Biosciences?

Suppliers matter to IDEAYA, but not in the same way they matter to a large industrial manufacturer. IDEAYA relies heavily on specialized external partners rather than vertically integrated production.

• Contract research organizations (CROs): Important for clinical operations, data management, and parts of preclinical work.
• Contract development and manufacturing organizations (CDMOs): Critical for active pharmaceutical ingredient production, formulation, packaging, and clinical trial supply.
• Central laboratories and biomarker-testing providers: Essential because patient selection is central to the company’s model.
• Specialized raw-material and chemistry suppliers: Needed for small-molecule development and manufacturing scale-up.
• Software and data vendors: Relevant for clinical trial management, safety systems, and regulatory documentation.

IDEAYA does not publicly disclose a long list of strategically named suppliers in the way a manufacturing company might. The strategic issue is supplier category structure: the company depends on quality, compliance, speed, and reliability from a relatively small number of specialized partners.

16. How Does the Supply Chain of IDEAYA Biosciences Function?

IDEAYA’s supply chain is best understood as a clinical-development supply chain. Because its lead assets are small molecules, the physical supply chain is generally simpler than that of cell therapy or large-molecule biologics, but it is still highly regulated and strategically important.

The chain typically runs from chemical sourcing and active ingredient manufacturing to formulation, packaging, labeling, and shipment to clinical sites. Alongside that physical chain is an equally important sample and data chain: tumor samples, genomic test results, and biomarker data must move reliably among sites, laboratories, and the sponsor.

Supply-chain performance matters for three reasons:

• Enrollment continuity: rare-cancer trials cannot afford drug shortages or site delays.
• Regulatory compliance: manufacturing controls and documentation must support later-stage filings.
• Program speed: in biotech, a delayed batch can delay a data readout and therefore delay value creation.

For IDEAYA, the supply chain is less about cost optimization than about de-risking development timelines.

17. What Is the Technology Strategy of IDEAYA Biosciences?

IDEAYA’s technology strategy is not about selling software or digital tools. It is about using precision-oncology technology capabilities to improve the odds of drug discovery and development. The core elements appear to be:

• Synthetic-lethality target identification to find vulnerabilities that are actionable in genetically defined cancers
• Translational biomarker development so patients can be selected with greater precision in trials
• Medicinal chemistry and small-molecule design to create drug candidates against difficult oncology targets
• Data integration across preclinical and clinical development to connect biology, patient selection, and readouts

Technology is therefore central to competitiveness, but mostly as an internal enabler. The customer-facing expression of that technology is a therapy matched to a biomarker-defined patient. In IDEAYA’s case, better technology should show up as cleaner target selection, faster proof of concept, and a higher probability of clinical differentiation.

18. What Is the R&D Strategy of IDEAYA Biosciences?

R&D is the core of IDEAYA’s business. The company’s research strategy is to focus on biologically validated targets with identifiable patient populations, then progress those programs with a combination of internal discovery and external partnerships.

Key features of the R&D strategy

• Biomarker-first development: IDEAYA tries to avoid broad, unselected oncology development whenever possible.
• Synthetic lethality as a repeatable engine: The company is trying to build multiple programs from a common scientific logic rather than one-off discoveries.
• Small, high-conviction portfolio design: IDEAYA appears to prefer a focused set of prioritized programs rather than an extremely broad but diluted pipeline.
• Combination optionality: In several settings, the company’s public strategy implies that combinations may be important for maximizing efficacy.
• External validation through partnerships: Collaborations with larger companies help validate the science and extend development reach.

The most important innovations are not consumer-visible brands; they are the underlying therapies and biomarker-development strategies. If IDEAYA succeeds, its R&D strategy will be validated not just by one approval but by a pattern of repeated clinical translation.

19. What Is the Finance Strategy of IDEAYA Biosciences?

IDEAYA’s finance strategy is shaped by one defining fact: it is a pre-commercial oncology biotech. That means finance is centered on runway, portfolio funding, and capital-allocation discipline, not on optimizing near-term earnings per share.

• Preserve cash to major catalysts: The company’s most important financial objective is to stay funded through key clinical readouts and development decisions.
• Use public equity markets opportunistically: Like many biotech companies, IDEAYA has relied on equity financing when conditions allow.
• Supplement with non-dilutive capital: Collaboration economics can reduce financing pressure and help support discovery work.
• Prioritize highest-value programs: Capital allocation must balance darovasertib, IDE397, IDE161, and earlier-stage efforts without spreading resources too thin.
• No income-oriented capital return model: Dividends and buybacks are not part of the investment case; reinvestment in R&D is.

For IDEAYA, the most relevant financial metrics are typically cash, cash burn, and funding horizon, not traditional margin measures. Finance strategy supports corporate strategy by ensuring that the company can advance multiple programs without being forced into unfavorable strategic choices by a weak balance sheet.

20. What Major Acquisitions Has IDEAYA Biosciences Made?

Traditional corporate acquisitions have not been a major feature of IDEAYA’s strategy. The company has relied more on asset licensing and strategic collaborations than on buying whole companies.

• Darovasertib: One of IDEAYA’s most important external portfolio moves was the in-licensing of darovasertib from Pfizer, which became the company’s lead uveal melanoma asset.
• GSK collaboration: IDEAYA entered a major synthetic-lethality collaboration with GSK, adding capital, external validation, and development optionality.
• Gilead collaboration: IDEAYA also formed a significant collaboration with Gilead, again using partnership rather than acquisition to expand its strategic reach.

The broader pattern is important. IDEAYA has preferred targeted business-development transactions over balance-sheet-intensive M&A. For a company at this stage, that is a rational choice: it preserves focus, limits integration risk, and lets management concentrate on clinical execution.

21. How Companies Like IDEAYA Biosciences Leverage Independent Consultants through Umbrex

For a company like IDEAYA, the need for consultants is usually not generic overhead reduction. It is targeted support on high-stakes decisions around pipeline prioritization, rare-oncology commercialization, clinical operations, diagnostics, finance, and partnering. Umbrex has built a global community of more than 8,000 independent management consultants based in more than 50 countries, including alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like IDEAYA use Umbrex when they need this level of problem-solving talent without hiring a full consulting team. Umbrex consultants cover Strategy, Operations, Organization, Marketing, Sales, Finance, Technology, ERP, and AI.

• Rare-oncology launch strategy: Develop a launch blueprint for darovasertib in metastatic uveal melanoma, including account segmentation, treatment-pathway mapping, and launch sequencing.
• Biomarker testing strategy: Design a patient-finding and testing ecosystem plan for GNAQ/GNA11, MTAP deletion, and homologous recombination deficiency.
• Portfolio prioritization: Build a decision framework to allocate capital across darovasertib, IDE397, IDE161, and earlier-stage programs.
• Commercial market-access planning: Create payer, evidence, and value-story strategies for a future targeted oncology launch.
• Clinical-operations acceleration: Redesign enrollment workflows, site prioritization, and vendor governance for rare-patient clinical trials.
• Ex-U.S. partnering strategy: Evaluate where IDEAYA should commercialize directly versus license or co-promote outside the United States.
• Competitive intelligence and scenario planning: Map competitor readouts in uveal melanoma, MTAP-deleted cancers, and synthetic lethality to inform development and investor messaging.
• CMC and supply-network readiness: Assess CDMO footprint, supply risk, and late-stage manufacturing readiness as programs mature.
• Finance and runway planning: Develop funding scenarios, milestone-based budgets, and capital-allocation choices tied to clinical catalysts.
• AI-enabled analytics support: Apply AI tools to trial-landscaping, literature synthesis, patient-identification workflows, or commercial-intelligence processes where appropriate.